https://wikimd.org/index.php?action=history&feed=atom&title=MosliciguatMosliciguat - Revision history2026-04-25T22:33:15ZRevision history for this page on the wikiMediaWiki 1.44.2https://wikimd.org/index.php?title=Mosliciguat&diff=6428627&oldid=prevPrab: CSV import2025-03-05T06:39:13Z<p>CSV import</p>
<p><b>New page</b></p><div>{{Short description|A soluble guanylate cyclase stimulator}}<br />
{{Drugbox<br />
| verifiedfields = changed<br />
| verifiedrevid = 477002123<br />
| image = [[File:Mosliciguat.svg|Chemical structure of Mosliciguat|thumb|right]]<br />
| IUPAC_name = 4-[[4-[[2-(1H-pyrazol-1-yl)ethyl]amino]-3-pyridinyl]amino]-5-methyl-2-(trifluoromethyl)pyrimidine<br />
| tradename = <br />
| legal_status = Investigational<br />
| routes_of_administration = Oral<br />
| bioavailability = <br />
| protein_bound = <br />
| metabolism = <br />
| elimination_half-life = <br />
| excretion = <br />
| CAS_number = 1610740-49-8<br />
| ATC_prefix = <br />
| ATC_suffix = <br />
| PubChem = 71587780<br />
| DrugBank = <br />
| ChemSpiderID = 32700863<br />
| UNII = <br />
| KEGG = <br />
| ChEMBL = 2103870<br />
| synonyms = <br />
}}<br />
<br />
'''Mosliciguat''' is a [[pharmaceutical drug]] that acts as a [[soluble guanylate cyclase]] (sGC) stimulator. It is currently under investigation for its potential therapeutic effects in treating various cardiovascular and pulmonary diseases.<br />
<br />
==Mechanism of Action==<br />
Mosliciguat works by stimulating the enzyme [[soluble guanylate cyclase]] (sGC), which is a key component in the [[nitric oxide]] (NO) signaling pathway. This enzyme catalyzes the conversion of [[guanosine triphosphate]] (GTP) to [[cyclic guanosine monophosphate]] (cGMP), a secondary messenger that plays a crucial role in [[vasodilation]], [[platelet aggregation]], and [[smooth muscle relaxation]]. By enhancing the activity of sGC, mosliciguat increases the levels of cGMP, leading to improved blood flow and reduced blood pressure.<br />
<br />
==Clinical Development==<br />
Mosliciguat is being studied for its potential use in treating conditions such as [[heart failure]], [[pulmonary hypertension]], and other cardiovascular disorders. Its ability to modulate the NO-sGC-cGMP pathway makes it a promising candidate for diseases characterized by impaired NO signaling.<br />
<br />
==Pharmacokinetics==<br />
The pharmacokinetic profile of mosliciguat includes its absorption, distribution, metabolism, and excretion. As an orally administered drug, it is designed to be absorbed through the gastrointestinal tract. The specifics of its metabolism and excretion are still under investigation, but it is known to have a half-life that supports once-daily dosing.<br />
<br />
==Potential Side Effects==<br />
As with any investigational drug, mosliciguat may have side effects. Commonly observed adverse effects in clinical trials include [[headache]], [[dizziness]], and [[hypotension]]. These effects are consistent with its mechanism of action as a vasodilator.<br />
<br />
==Research and Development==<br />
Research on mosliciguat is ongoing, with several clinical trials being conducted to evaluate its efficacy and safety in various patient populations. The outcomes of these studies will determine its potential approval and use in clinical practice.<br />
<br />
==Related Pages==<br />
* [[Soluble guanylate cyclase]]<br />
* [[Nitric oxide]]<br />
* [[Cyclic guanosine monophosphate]]<br />
* [[Vasodilation]]<br />
* [[Heart failure]]<br />
* [[Pulmonary hypertension]]<br />
<br />
[[Category:Cardiovascular drugs]]<br />
[[Category:Investigational drugs]]</div>Prab